Tag Archives: What is C. difficile?

A Global Stroll In the Park To Raise C. diff. Awareness On September 25th

Join Us For a Stroll In the Park on September 25th In-Person, and On-Line To Raise C. diff. Awareness Around the Globe!

 

 

 

 

September 25th is right around the corner and we are so excited to have this opportunity to walk together either in-person at the following park locations:

Sims Park, New Port Richey, FL

Milton A. Votee Park, Teaneck, NJ 

Brown Street Park Complex, Spring City, PA

 

 

 

 

 

 

We are truly grateful for your efforts, support, and participation of the Annual Walk events and it will be amazing to walk, or stroll,  with you on a path in a local park, or virtually on a path across the globe on September 25th from 9:00 a.m. – 12:00 p.m. EST

 

Walking, and Strolling,  is a fun, and relaxing way  to enjoy a change of scenery. Taking a stroll among the pleasant sights and sounds of nature, in-person or online,  has the ability to renew the mind and body simultaneously. Walking with your family, and friends, for a cause is even better ~ as you join the many C. diff. Awareness Walkers around the world sharing time to Raise C. diff. Awareness while spending time together to enjoy a way to add a little extra positive activity of the day.

All Registered Awareness Walkers will receive:

A C. diff. Awareness T-Shirt
C. diff. Awareness Literature and Giveaways,
The opportunity to “Raise C. diff. Awareness” together worldwide!
* Children 10 years of age and under walk for free!

  • All items will be sent directly to all registered Awareness Walkers to the address provided in the registration.

To Register For This Global Event, Please Click On The Button Below:

 

 

 

 

 

SPONSORS

We thank the Sponsors for their support of the global walks, and for joining us in  “Raising C. diff. Awareness” across the globe.

Click on the graphics below to visit the Sponsor’s website and learn more about the organizations that are making a difference in the C. diff. community worldwide.

 

 

 

 

We are looking forward to seeing you in September!

If you have any questions — please direct them to info@cdifffoundation.org or telephone the main C Diff Foundation office:  +1 (727) 205-3922

 


2020 C. diff. Awareness Walkers

Seres Therapeutics and Nestle’ Health Science Team Up For the Joint Commercialization of Seres Therapeutics Investigational Microbiome Treatment for Recurrent C. difficile Infection (rCDI)

Seres Therapeutics and Nestlé Health Science have announced a decision to team up for the joint commercialization of Seres’s investigational oral microbiome treatment for recurrent Clostridioides difficile (C. difficile) infections (CDI).

Nestlé Health Science had previously received commercial rights to Seres’s therapeutics for inflammatory bowel disease and CDI, but only outside the U.S. and Canada. This expansion places Nestlé as Seres’s global collaborator for SER-109, a therapy the company hopes to treat a leading contributor to hospital-acquired infections in North America. If approved by the U.S. Food and Drug Administration (FDA), the agent, dubbed SER-109, will be the first microbiome therapeutic available.

Each year, CDI contributes to the deaths of 20,000 Americans. Standard of care for recurrent CDI includes the use of fecal microbial transplants. Currently, there is no microbiome therapies approved for any indications, which has created an unmet need recognized by an ever-growing list of pharmaceutical companies partnering with microbiome startups.

Seres’s investigational SER-109 includes purified Firmicutes spores; the rationale for including these spores is “based on their modulatory role in the life cycle of C. difficile and disease pathogenesis,” according to a statement made by the company.

Findings from the pivotal Phase III ECOSPOR III trial announced back in August 2020 showed SER-109 significantly reduced the CDI recurrence rate compared with placebo over an eight-week period. The absolute reduction of the CDI recurrence rate was 27% while the relative risk reduction was 68%. In addition, up to 88% of patients experienced a sustained clinical response by the end of the eight weeks.

Nestlé Health Science has agreed to use Aimmune Therapeutics, the company’s global pharmaceutical business, to lead the commercialization of the therapy. In return, Seres has agreed to receive upfront licensing payments totaling $175 million. An additional $125 million will be paid to Seres by Nestlé upon FDA approval of the microbiome agent.

Under terms of the agreement, Seres holds the sole responsibility for costs associated with development and pre-commercialization of SER-109 in the U.S. The company will be eligible to receive up to 50% of the commercial profits once the therapeutic is commercialized.

“Nestlé Health Science has been a terrific collaborator in our quest to develop a new treatment option for patients suffering from recurrent C. difficile infection, and their support over the past few years has been critical in advancing SER-109 to address this unmet need,” said Eric Shaff, Seres Therapeutics’ chief executive officer, in a statement. “As we prepare for potential approval and commercialization, we are eager to embark side-by-side on our next phase with a company that believes as fervently as we do in the potential of this transformative approach to reduce the recurrence of CDI.”

Nestlé Health Science’s CEO, Greg Behar, added that the company “is focused on the fast-developing areas of gut health, food allergies and metabolic health within our global pharmaceutical business, Aimmune Therapeutics.” As such, Aimmune’s “fully integrated commercial infrastructure” will be leveraged to launch the therapy, pending approval.

Seres has been busy this year in moving its investigational microbiome therapy pipeline in front of the FDA. Last month, Seres announced the agency had cleared an Investigational New Drug application for the company’s other investigational microbiome therapeutic for preventing antibiotic-resistant bacterial infections as well as graft-versus-host disease.

The company is advancing SER-155 into a Phase Ib trial under a collaboration with Memorial Sloan Kettering Cancer Center. “SER-155 represents a novel microbiome technology with the potential to address antibiotic-resistant bacterial bloodstream infections and further to modulate host immunomodulatory responses to decrease graft-versus-host disease,” said Seres’s chief scientific officer, Matthew Henn, Ph.D., in a statement.

 

SOURCE:  https://www.biospace.com/article/seres-nestle-agree-to-jointly-commercialize-microbiome-agent-for-c-diff-infections/